CPRX Catalyst Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CPRX

Price (delayed)

$31.4

Market cap

$3.84B

P/E Ratio

17.35

Dividend/share

N/A

EPS

$1.81

Enterprise value

$3.09B

?
Relative Growth: Rel. Growth: 93
Relative Strength: Rel. Strength: 81
Relative Valuation: Rel. Valuation: 64
Relative Profitability: Rel. Profitability: 97

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK ...

Highlights
Catalyst Pharmaceuticals's equity has increased by 27% YoY and by 6% QoQ
Catalyst Pharmaceuticals's quick ratio has increased by 18% QoQ and by 15% YoY
The stock's P/E is 38% more than its last 4 quarters average of 12.6 and 2.7% more than its 5-year quarterly average of 16.9
Sector: Healthcare
Industry: Biotechnology
Website: http://www.catalystpharma.com
Peers: SRPT JNJ BMRN ABT

Key stats

What are the main financial stats of CPRX

CPRX stock price

How has the Catalyst Pharmaceuticals stock price performed over time
Intraday
0.06%
1 week
0.16%
1 month
0.45%
1 year
41.95%
YTD
34.53%
QTD
26.82%

Financial performance

How have Catalyst Pharmaceuticals's revenue and profit performed over time
Revenue
$596.96M
Gross profit
$513.14M
Operating income
$267.64M
Net income
$221.32M
Gross margin
86%
Net margin
37.1%
The company's operating income rose by 16% YoY and by 3.8% QoQ
The revenue rose by 12% YoY
Catalyst Pharmaceuticals's net income has increased by 12% YoY and by 3.3% QoQ
Catalyst Pharmaceuticals's gross profit has increased by 11% YoY and by 2.3% QoQ

Price vs fundamentals

How does CPRX's price correlate with its fundamentals

Growth

What is Catalyst Pharmaceuticals's growth rate over time

Valuation

What is Catalyst Pharmaceuticals stock price valuation
CPRX P/E details
P/E
17.35
P/B
3.79
P/S
6.43
EV/EBIT
10.42
EV/EBITDA
9.22
EV/Sales
5.17
The stock's P/E is 38% more than its last 4 quarters average of 12.6 and 2.7% more than its 5-year quarterly average of 16.9
The EPS has increased by 10% year-on-year and by 3.4% since the previous quarter
The stock's price to book (P/B) is 31% more than its last 4 quarters average of 2.9 and 2.4% more than its 5-year quarterly average of 3.7
Catalyst Pharmaceuticals's equity has increased by 27% YoY and by 6% QoQ
The price to sales (P/S) is 37% higher than the last 4 quarters average of 4.7 and 26% higher than the 5-year quarterly average of 5.1
The revenue rose by 12% YoY

Efficiency

How efficient is Catalyst Pharmaceuticals business performance
The ROIC is down by 32% year-on-year and by 12% since the previous quarter
The ROE has decreased by 16% YoY and by 2.5% from the previous quarter
CPRX's return on assets is down by 15% year-on-year and by 2.4% since the previous quarter
The ROS has increased by 3.3% since the previous quarter and by 2.9% year-on-year

Dividends

What is CPRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CPRX.

Financial health

How did Catalyst Pharmaceuticals financials performed over time
The total assets is up by 26% year-on-year and by 4% since the previous quarter
The total liabilities rose by 18% YoY but it fell by 10% QoQ
Catalyst Pharmaceuticals's debt is 100% lower than its equity
Catalyst Pharmaceuticals's equity has increased by 27% YoY and by 6% QoQ
Catalyst Pharmaceuticals's debt has decreased by 17% YoY and by 4.9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.